相似文献
1
Biomarkers in community-acquired pneumonia: a state-of-the-art review.
Clinics (Sao Paulo). 2012 Nov;67(11):1321-5. doi: 10.6061/clinics/2012(11)17.
2
Biomarkers for predicting short-term mortality in community-acquired pneumonia: A systematic review and meta-analysis.
J Infect. 2016 Mar;72(3):273-82. doi: 10.1016/j.jinf.2016.01.002. Epub 2016 Jan 15.
3
Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia.
J Infect. 2015 May;70(5):457-66. doi: 10.1016/j.jinf.2014.12.003. Epub 2014 Dec 11.
4
Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia.
Crit Care. 2010;14(1):203. doi: 10.1186/cc8155. Epub 2010 Feb 8.
5
The usefulness of serum procalcitonin, C-reactive protein, soluble triggering receptor expressed on myeloid cells 1 and Clinical Pulmonary Infection Score for evaluation of severity and prognosis of community-acquired pneumonia in elderly patients.
Arch Gerontol Geriatr. 2019 Jan-Feb;80:53-57. doi: 10.1016/j.archger.2018.10.005. Epub 2018 Oct 12.
6
Biomarkers and community-acquired pneumonia: tailoring management with biological data.
Semin Respir Crit Care Med. 2012 Jun;33(3):266-71. doi: 10.1055/s-0032-1315638. Epub 2012 Jun 20.
7
C-terminal provasopressin (copeptin) in patients with community-acquired pneumonia--influence of antibiotic pre-treatment: results from the German competence network CAPNETZ.
J Antimicrob Chemother. 2009 Jul;64(1):159-62. doi: 10.1093/jac/dkp148. Epub 2009 Apr 29.
8
Pro-atrial natriuretic peptide and pro-vasopressin for predicting short-term and long-term survival in community-acquired pneumonia: results from the German Competence Network CAPNETZ.
Thorax. 2010 Mar;65(3):208-14. doi: 10.1136/thx.2009.121178.
9
Prognostic value of mid-regional pro-adrenomedullin (MR-proADM) in patients with community-acquired pneumonia: a systematic review and meta-analysis.
BMC Infect Dis. 2016 May 26;16:232. doi: 10.1186/s12879-016-1566-3.
10
The Role of Biomarkers in the Diagnosis and Management of Pneumonia.
Infect Dis Clin North Am. 2024 Mar;38(1):35-49. doi: 10.1016/j.idc.2023.12.005.
引用本文的文献
1
Role of Inflammatory Markers as a Risk Factor for Community-Acquired Pneumonia Management.
Medicina (Kaunas). 2025 Jun 11;61(6):1078. doi: 10.3390/medicina61061078.
2
A Review on Risk Factors, Traditional Diagnostic Techniques, and Biomarkers for Pneumonia Prognostication and Management in Diabetic Patients.
Diseases. 2024 Dec 2;12(12):310. doi: 10.3390/diseases12120310.
3
C-Reactive Protein as a Predictor of Survival and Length of Hospital Stay in Community-Acquired Pneumonia.
J Pers Med. 2022 Oct 13;12(10):1710. doi: 10.3390/jpm12101710.
4
Circulating Thrombomodulin: Release Mechanisms, Measurements, and Levels in Diseases and Medical Procedures.
TH Open. 2022 Jul 11;6(3):e194-e212. doi: 10.1055/a-1801-2055. eCollection 2022 Jul.
5
Association of soluble receptor for advanced glycation end-products (sRAGE) serum on COVID-19 severity: A cross-sectional study.
Ann Med Surg (Lond). 2022 Feb;74:103303. doi: 10.1016/j.amsu.2022.103303. Epub 2022 Jan 29.
6
Footprints of Sepsis Framed Within Community Acquired Pneumonia in the Blood Transcriptome.
Front Immunol. 2018 Jul 17;9:1620. doi: 10.3389/fimmu.2018.01620. eCollection 2018.
7
How and when to use common biomarkers in community-acquired pneumonia.
Pneumonia (Nathan). 2016 Oct 28;8:17. doi: 10.1186/s41479-016-0017-7. eCollection 2016.
8
Biomarkers in Pediatric Community-Acquired Pneumonia.
Int J Mol Sci. 2017 Feb 19;18(2):447. doi: 10.3390/ijms18020447.
9
Prognostic value of on admission arterial PCO in hospitalized patients with community-acquired pneumonia.
J Thorac Dis. 2016 Oct;8(10):2765-2771. doi: 10.21037/jtd.2016.10.21.
10
Usefulness of midregional proadrenomedullin to predict poor outcome in patients with community acquired pneumonia.
PLoS One. 2015 Jun 1;10(6):e0125212. doi: 10.1371/journal.pone.0125212. eCollection 2015.
本文引用的文献
1
Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ.
Am J Respir Crit Care Med. 2010 Dec 1;182(11):1426-34. doi: 10.1164/rccm.201003-0415OC. Epub 2010 Jul 16.
2
Adrenal response in severe community-acquired pneumonia: impact on outcomes and disease severity.
Chest. 2008 Nov;134(5):947-954. doi: 10.1378/chest.08-1382. Epub 2008 Aug 27.
3
Prognostic value of midregional pro-atrial natriuretic peptide in ventilator-associated pneumonia.
Intensive Care Med. 2008 Nov;34(11):2084-91. doi: 10.1007/s00134-008-1173-x. Epub 2008 Jun 4.
4
C-reactive protein is an independent predictor of severity in community-acquired pneumonia.
Am J Med. 2008 Mar;121(3):219-25. doi: 10.1016/j.amjmed.2007.10.033.
5
Copeptin, a novel prognostic biomarker in ventilator-associated pneumonia.
Crit Care. 2008;12(1):R11. doi: 10.1186/cc6780. Epub 2008 Feb 2.
6
C-reactive protein, inflammatory conditions, and cardiovascular disease risk.
Am J Med. 2007 Dec;120(12):1054-62. doi: 10.1016/j.amjmed.2007.08.037.
7
Biomarkers to improve diagnostic and prognostic accuracy in systemic infections.
Curr Opin Crit Care. 2007 Oct;13(5):578-85. doi: 10.1097/MCC.0b013e3282c9ac2a.
8
Usefulness of C-reactive protein in monitoring the severe community-acquired pneumonia clinical course.
Crit Care. 2007;11(4):R92. doi: 10.1186/cc6105.
9
Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia.
BMC Infect Dis. 2007 Mar 2;7:10. doi: 10.1186/1471-2334-7-10.
10
Cardiovascular consequences of cortisol excess.
Vasc Health Risk Manag. 2005;1(4):291-9. doi: 10.2147/vhrm.2005.1.4.291.
Zotero 插件